Futibatinib (Lytgobi) is a rare alkyne-containing, irreversible FGFR1-4 inhibitor that received accelerated approval from the FDA in September 2022. Structurally distinct from other approved FGFR2/3 inhibitors, futibatinib treats a range of FGFR-aberrant tumors, including those with fusions or TKI-resistant mutants like the V565I/L gatekeeper mutation.
This Premium report reviews:
- the role of FGFR mutations in oncogenesis and drug resistance
- differences between approved and emerging FGFR inhibitors
- human data on futibatinib, including PK and efficacy
See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.